Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cells

31 Jul 2020

Abstract excerpt

Despite considerable efforts, mTOR inhibitors have produced limited success in the clinic. To define the vulnerabilities of mTORC1-addicted cancer cells and to find previously unknown therapeutic targets, we investigated the mechanism of piperlongumine, a small molecule identified in a chemical library screen to specifically target cancer cells with a hyperactive mTORC1 phenotype. Sensitivity to piperlongumine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to CRISPR and Genetic Engineering

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 32789167
DOI: 10.1126/sciadv.aay9131

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic lethality by targeting the RUVBL1/2-TTT complex in mTORC1-hyperactive cancer cellsPMID 32789167Read ↗

RUVBL1 and RUVBL2 are druggable MYCN regulators in neuroblastomaSemantic proximity Read ↗

mTOR Inhibitors in Cancer: What Can We Learn from Exceptional Responses?Semantic proximity Read ↗

mTOR is a Major Determinant of ChemosensitivitySemantic proximity Read ↗

Yeast Phenomic Analysis Reveals DNA Repair, pH Homeostasis, and Ribosomal Biogenesis as Modulators of Anticancer Ruthenium Complex KP1019.Semantic proximity Read ↗

The novel RNA polymerase I transcription inhibitor PMR-116 exploits a critical therapeutic vulnerability in a broad-spectrum of high <i>MYC</i> malignanciesSemantic proximity Read ↗

Multimodal interrogation establishes the AAA+ ATPase RUVBL1 as a prognostic driver and tractable dependency in malignant pleural mesotheliomaSemantic proximity Read ↗

MYC and therapy resistance in cancer: risks and opportunitiesSemantic proximity Read ↗

Lurbinectedin Specifically Triggers the Degradation of Phosphorylated RNA Polymerase II and the Formation of DNA Breaks in Cancer CellsSemantic proximity Read ↗

Topoisomerase 1 Inhibition in MYC-Driven Cancer Promotes Aberrant R-Loop Accumulation to Induce Synthetic LethalitySemantic proximity Read ↗

Structurally diverse c-Myc inhibitors share a common mechanism of action involving ATP depletionSemantic proximity Read ↗

PI3K/mTOR activity sensitizes cancer cells to nucleolar stressSemantic proximity Read ↗

RUVBL1 and RUVBL2 as novel druggable DNA Damage Response regulators in the N-Myc regulatory network in neuroblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.